# Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides

> **NCT02943642** · PHASE2 · WITHDRAWN · sponsor: **Virogen Biotechnology Inc.**

## Conditions studied

- Mycosis Fungoides

## Interventions

- **BIOLOGICAL:** A-dmDT390-bisFv(UCHT1)
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT02943642
- **Lead sponsor:** Virogen Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-05
- **Primary completion:** 2026-05-13
- **Final completion:** 2026-05-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This record is an earlier version (crossover design). After FDA-approved IND sponsor transfer to Virogen, the study was redesigned. This protocol will never start. The new protocol is NCT07529405.
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02943642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02943642, "Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT02943642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*